Impact of radiation schedule and chemotherapy duration in definitive chemoradiotherapy regimen for esophageal cancer

Frédéric Di Fiore(Université Paris Cité), Pierre Michel(Aix-Marseille Université), Brigitte Vié(Centre François Baclesse), Olivier Rigal(Centre Henri Becquerel), Marie‐Pierre Galais(Centre François Baclesse), Stéphane Lecleire(Inserm), H. Hamidou(Laboratoire National Henri Becquerel), I. David(Centre François Baclesse), Jacques‐Henri Jacob(Centre François Baclesse), B Paillot(Centre Henri Becquerel)

Gastroentérologie Clinique et Biologique

July 1, 2006

10.1016/s0399-8320(06)73331-0

Cited by 15

Related Papers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

|New England Journal of Medicine|2018|2.9k

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

|BMJ|2022|494

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

|The Lancet Oncology|2014|451

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

|European Journal of Cancer|1997|347

The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients With Differences According to the Disease Subtype

|The American Journal of Gastroenterology|2011|290